Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Xlife Sciences Ltd. ( (CH:XLS) ) has shared an update.
Xlife Sciences AG has announced a strategic exit of 12 project companies to Grupo Landsteiner, valued at USD 450 million, to form a scalable transcontinental life sciences platform. This transaction, structured as an asset deal, will integrate Xlife’s technologies into Landsteiner’s operations, fostering a long-term collaboration aimed at innovation and market expansion. The new entity plans a NASDAQ listing in 2026, providing access to international investors and strengthening oncology care in Mexico. This partnership is expected to create a vertically integrated company combining Swiss innovation with Latin American production, enhancing global market access and sustainable growth.
More about Xlife Sciences Ltd.
Xlife Sciences AG is a Swiss company that functions as an incubator and accelerator, focusing on the development and commercialization of promising research projects from universities and other research institutions in the life sciences sector. The company aims to bridge the gap between research and development and healthcare markets by advancing projects in technology platforms, biotechnology, medtech, and artificial intelligence/digital health.
Average Trading Volume: 3,075
Technical Sentiment Signal: Buy
Current Market Cap: CHF129.8M
See more insights into XLS stock on TipRanks’ Stock Analysis page.